BioSpace News Archive

Prescient , a biopharma product and portfolio strategy partner, announces the recent appointment of three new senior members: Gordon Gochenauer , Dr. Priya Kar and Dr. Cameron Mackenzie . They join the e

Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapeutics to cure viral infectious diseases, announced today the first appointees of its Business Advisory Board and its new Interim Chief Business Officer. This group of industry veterans will help steer the company to bring lifesaving, curative medications to patients in need, as well as to build one of the strongest companies in biotech. “We are extremely for

-- KEYNOTE-695 abstract selected to be featured for discussion led by Dr. Adil Daud during Virtual Poster Walk -- -- Company Symposium featuring Dr. Paolo Ascierto’s discussion of KEYNOTE-695 data to be held on November 12, 2020 at 7:30 a.m. ET -- -- Additional abstracts on CORVax12, OncoSec’s COVID-19 vaccine candidate, and on TAVO in metastatic TNBC selected as poster presentations --

The platform aims to accelerate innovation by giving consumers a cutting-edge means of sharing health data with the enterprises and researchers putting it to good use

Twistle today announced it has been named as a finalist for the 2020 TripleTree iAwards . In its evaluation of award applicants, TripleTree selected 10 companies with the greatest potential to deliver innovative sol

ResMed Announces Participation in the Credit Suisse 29 th Annual Global Healthcare Conference

Noveome Biotherapeutics, Inc. to Present at the 10 th Annual Traumatic Brain Injury Conference (Virtual), November 2-4, 2020

Medical technology company joins the fight against the coronavirus making fast, accurate diagnosis tool available at no cost

Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary platform, today provided an update on its ongoing APVO436 Phase 1 clinical trial.

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry of Health authorized the initiation of a proposed Company-sponsored Phase IIb clinical trial evaluating Allocetra ™ , in sepsis patients. The planned Company-sponsored Phase IIb clinical trial is a multi-center, randomized, placebo-controlled study, which is expected to recruit up to 160 sepsis patients